Literature DB >> 28161699

Appropriate Follow-Up Strategies for Gastrointestinal Stromal Tumor Patients Based on the Analysis of Recurrent Interval and Patterns.

Noriko Wada1, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Toru Masuzawa, Rie Nakatsuka, Junji Kawada, Toshirou Nishida, Yutaka Kimura, Kouji Tanaka, Yasuhiro Miyazaki, Tomoki Makino, Makoto Yamasaki, Shuji Takiguchi, Masaki Mori, Yuichiro Doki.   

Abstract

BACKGROUND/AIMS: Previous studies have proposed risk classifications for patients with gastrointestinal stromal tumor (GIST) after resection and have contributed to the prediction of its prognosis. However, optimal postoperative surveillance has not yet been established.
METHODS: We retrospectively analyzed data from 115 GIST patients who experienced recurrence after complete resection. The relationships between clinicopathological characteristics and the first recurrence sites, or time to recurrence (TTR), were investigated. We also compared the characteristics between 2 subgroups based on a TTR of ≤5 or >5 years.
RESULTS: The first recurrence occurred in the abdomen in 114 of 115 patients (99.1%); one case of esophageal GIST recurred in the lung. Gastric and small intestinal GISTs recurred most frequently in the liver or peritoneum, while the most common recurrences of colorectal GISTs were found to be local. Fourteen patients (12.2%) experienced recurrence after >5 years. Smaller tumors and those categorized as lower risk were significantly more frequent in the TTR >5 years group than in the TTR ≤5 years group. In the TTR >5 years group, local recurrence was the most frequent type of recurrence (42.9%).
CONCLUSION: Based on abdominal examination, postoperative surveillance after complete resection for primary GISTs may be recommended for >5 years.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2017        PMID: 28161699     DOI: 10.1159/000452656

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  3 in total

1.  Clinicopathologic Characteristics and Optimal Surgical Treatment of Duodenal Gastrointestinal Stromal Tumor.

Authors:  Seung Jae Lee; Ki Byung Song; Young-Joo Lee; Song Cheol Kim; Dae Wook Hwang; Jae Hoon Lee; Sang Hyun Shin; Jae Woo Kwon; Seung Hyun Hwang; Chung Hyeun Ma; Gui Suk Park; Ye Jong Park; Kwang-Min Park
Journal:  J Gastrointest Surg       Date:  2018-08-21       Impact factor: 3.452

2.  Real-world data on the efficacy and safety of adjuvant chemotherapy in Japanese patients with a high-risk of gastrointestinal stromal tumor recurrence.

Authors:  Yuki Ushimaru; Tsuyoshi Takahashi; Kiyokazu Nakajima; Ryugo Teranishi; Toshirou Nishida; Seiichi Hirota; Masaaki Motoori; Takeshi Omori; Ryohei Kawabata; Kazuhiro Nishikawa; Takuro Saito; Kotaro Yamashita; Koji Tanaka; Tomoki Makino; Kazuyoshi Yamamoto; Yukinori Kurokawa; Hidetoshi Eguchi; Yuichiro Doki
Journal:  Int J Clin Oncol       Date:  2022-02-12       Impact factor: 3.402

3.  Utility of noncontrast MRI in the detection and risk grading of gastrointestinal stromal tumor: a comparison with contrast-enhanced CT.

Authors:  Ziling Zhou; Jingyu Lu; John N Morelli; Daoyu Hu; Zhen Li; Peng Xiao; Xuemei Hu; Yaqi Shen
Journal:  Quant Imaging Med Surg       Date:  2021-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.